a study of jnj-87562761 in participants with relapsed or refractory multiple myeloma

Conditions: Relapsed or Refractory Multiple Myeloma

Summary: the purpose of this study is to determine the recommended phase 2 dose(s) (rp2d\[s\]) of jnj-87562761 in part 1 (dose escalation), and to determine the safety and tolerability at rp2d in part 2 (dose expansion) in participants with multiple myeloma (mm) whose disease has come back after treatment (relapsed) or hasn't responded to treatment (refractory).


Eligibility criteria:
inclusion criteria: * relapsed, refractory multiple myeloma with measurable disease defined as: (a) serum monoclonal paraprotein (m-protein) level greater than (\>)0.5 grams per deciliter (g/dl); or (b) urine m-protein level \>200 milligrams per 24 hours (mg/24 hours); or (c) light chain multiple myeloma: serum immunoglobulin free light chain (flc) \>10 milligrams per deciliter (mg/dl) and abnormal serum immunoglobulin kappa-lambda flc ratio * must have had prior therapy including a proteasome inhibitor, immunomodulatory agent and anti-cd38 therapy * have an eastern cooperative oncology group (ecog) performance status of 0 to 1 * have an estimated glomerular filtration rate (egfr), of \> 30 millilitres (ml)/min/1.73 meter square (m\^2) computed with the online calculator on the chronic kidney disease epidemiology collaboration (ckd-epi) by use of the ckd-epi serum creatinine (cr) result * while on study treatment and for 6 months after the last dose of study treatment, a participant must: (a) not breastfeed or be pregnant; (b) not donate gametes (that is, eggs or sperm) or freeze for future use for the purposes of assisted reproduction; (c) wear an external condom exclusion criteria: * active plasma cell leukemia, waldenström's macroglobulinemia, poems syndrome (polyneuropathy, organomegaly, endocrinopathy, m-protein, and skin changes), or immunoglobulin light chain amyloidosis * prior allogeneic transplant within 6 months before the start of study treatment administration or autologous transplant within 12 weeks before the start of study treatment administration * live, attenuated vaccine within 4 weeks before the first dose of study treatment * central nervous system (cns) involvement or clinical signs of meningeal involvement of multiple myeloma. if either is suspected, brain magnetic resonance imaging (mri) and lumbar cytology are required * non-hematologic toxicity from prior anticancer therapy that has not resolved to baseline level or to less than or equal to (\<=) grade 1 (except alopecia, tissue post-rt fibrosis, or grade \< 3 peripheral neuropathy) * received a cumulative dose of corticosteroids equivalent to greater than (\>) 140 mg of prednisone within the 14-day period before the start of study treatment administration * prior antitumor therapy in the specified time frame prior to the first dose of study treatment: (targeted therapy, epigenetic therapy, monoclonal antibody treatment, or treatment with an investigational drug or an invasive investigational medical device or conventional chemotherapy within 21 days, gene-modified adoptive cell therapy or treatment with anti-cd38 directed therapies within 3 months, proteasome inhibitor \[pi\] therapy or radiotherapy within 14 days, or immunomodulatory drug (imid) agent therapy within 7 days) * following medical conditions: pulmonary compromise requiring supplemental oxygen use to maintain adequate oxygenation, human immunodeficiency (hiv) infection (participants with a detectable viral load or low cd4 count), active hepatitis b or c infection, active autoimmune disease requiring systemic immunosuppressive therapy within 6 months before start of study treatment, serious uncontrolled ongoing viral or bacterial or systemic fungal infection, cardiac conditions (myocardial infarction \<=6 months prior to enrollment, new york heart association stage iii or iv congestive heart failure, et cetera \[etc.\] )